A detailed history of Goldman Sachs Group Inc transactions in Denali Therapeutics Inc. stock. As of the latest transaction made, Goldman Sachs Group Inc holds 1,218,925 shares of DNLI stock, worth $32.7 Million. This represents 0.0% of its overall portfolio holdings.

Number of Shares
1,218,925
Previous 904,361 34.78%
Holding current value
$32.7 Million
Previous $18.6 Million 52.52%
% of portfolio
0.0%
Previous 0.0%

Shares

18 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q2 2024

Aug 13, 2024

BUY
$14.96 - $23.22 $4.71 Million - $7.3 Million
314,564 Added 34.78%
1,218,925 $28.3 Million
Q1 2024

May 15, 2024

BUY
$15.83 - $23.35 $8.08 Million - $11.9 Million
510,556 Added 129.65%
904,361 $18.6 Million
Q4 2023

Feb 13, 2024

SELL
$16.2 - $23.18 $220,125 - $314,969
-13,588 Reduced 3.34%
393,805 $8.45 Million
Q3 2023

May 14, 2024

BUY
$20.63 - $30.17 $280,320 - $409,949
13,588 Added 3.45%
407,393 $8.4 Million
Q3 2023

Nov 14, 2023

SELL
$20.63 - $30.17 $4.9 Million - $7.17 Million
-237,521 Reduced 36.83%
407,393 $8.4 Million
Q2 2023

May 14, 2024

BUY
$23.37 - $32.96 $1.68 Million - $2.38 Million
72,071 Added 12.58%
644,914 $19 Million
Q2 2023

Aug 14, 2023

BUY
$23.37 - $32.96 $1.68 Million - $2.38 Million
72,071 Added 12.58%
644,914 $19 Million
Q1 2023

May 14, 2024

SELL
$21.91 - $32.67 $4.35 Million - $6.49 Million
-198,609 Reduced 25.74%
572,843 $13.2 Million
Q1 2023

May 11, 2023

SELL
$21.91 - $32.67 $4.35 Million - $6.49 Million
-198,609 Reduced 25.74%
572,843 $13.2 Million
Q4 2022

May 14, 2024

BUY
$26.28 - $33.92 $1.13 Million - $1.46 Million
43,180 Added 5.93%
771,452 $21.5 Million
Q4 2022

Feb 13, 2023

BUY
$26.28 - $33.92 $1.13 Million - $1.46 Million
43,180 Added 5.93%
771,452 $21.5 Million
Q3 2022

May 14, 2024

BUY
$25.97 - $38.53 $7.99 Million - $11.8 Million
307,530 Added 73.09%
728,272 $22.4 Million
Q3 2022

Nov 10, 2022

BUY
$25.97 - $38.53 $7.99 Million - $11.8 Million
307,530 Added 73.09%
728,272 $22.4 Million
Q2 2022

May 14, 2024

BUY
$20.88 - $35.19 $562,444 - $947,913
26,937 Added 6.84%
420,742 $12.4 Million
Q2 2022

Aug 15, 2022

BUY
$20.88 - $35.19 $303,052 - $510,747
14,514 Added 3.57%
420,742 $12.4 Million
Q1 2022

May 16, 2022

SELL
$29.0 - $47.27 $131,544 - $214,416
-4,536 Reduced 1.1%
406,228 $13.1 Million
Q4 2021

Feb 14, 2022

SELL
$42.59 - $55.02 $27.5 Million - $35.5 Million
-645,794 Reduced 61.12%
410,764 $18.3 Million
Q3 2021

Nov 10, 2021

BUY
$48.48 - $78.23 $51.2 Million - $82.7 Million
1,056,558 New
1,056,558 $53.3 Million

Others Institutions Holding DNLI

About Denali Therapeutics Inc.


  • Ticker DNLI
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 134,174,000
  • Market Cap $3.6B
  • Description
  • Denali Therapeutics Inc., a biopharmaceutical company, discovers and develops therapeutic candidates for neurodegenerative diseases in the United States. It offers leucine-rich repeat kinase 2 (LRRK2) inhibitor product candidate, including BIIB122/DNL151, a small molecule inhibitor, which is in phase I and phase Ib clinical trials for the treatm...
More about DNLI
Track This Portfolio

Track Goldman Sachs Group Inc Portfolio

Follow Goldman Sachs Group Inc and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Goldman Sachs Group Inc, based on Form 13F filings with the SEC.

News

Stay updated on Goldman Sachs Group Inc with notifications on news.